New First-In-Class Treatment Fycompa® Launches Today for People With the Most Common Form of Epilepsy

New First-In-Class Treatment Fycompa® Launches Today for People With the Most Common Form of Epilepsy PR Newswire HATFIELD, England, September 13, 2012 HATFIELD, England, September 13, 2012 /PRNewswire/ -- Europe first region in the world to gain access to this new therapy for partial seizures ®Fycompa (perampanel) is the first in a new class of epilepsy treatments, with demonstrated efficacy in partial onset seizures, in particular with secondary [1]generalisations. In Europe, perampanel is indicated for use as an adjunctive treatment for partial onset seizures, with or without secondarily generalised [1]seizures, in patients with epilepsy aged 12 years and older. Following the UK launch, perampanel will also be launched in Germany, Austria and Denmark this month. Discovered and developed by Eisai in the UK and Japan, perampanel is the first and only licensed anti-epileptic drug (AED) to selectively target AMPA receptors, a receptor in the brain which plays a critical role in the initiation and spread of [2]seizures. This mechanism of action is different to any other licensed AEDs. In addition, perampanel has the added benefit of convenient, once-daily dosing at [1]bedtime and significantly, is the only third generation partial-onset epilepsy treatment licensed to treat adolescent epilepsy from launch. Improved epilepsy care is crucial.